| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A14 |
| Uniprot No | Q9HCY8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-104aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGQCRSANAEDAQEFSDVERAIE TLIKN FHQYSVEGGKETLTPSELRDLVTQQLPHLMPSNCGLEEKIANLGS CND SKLEFRSFWELIGEAAKSVKLERPVRGH |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与S100A14重组蛋白相关的研究文献概览：
1. **文献名称**: *S100A14 promotes progression and metastasis in colorectal cancer via interaction with RAGE*
**作者**: Chen H et al.
**摘要**: 通过大肠癌细胞模型验证S100A14重组蛋白可通过结合RAGE受体激活MAPK/ERK通路，促进肿瘤细胞迁移和侵袭，首次揭示其在结直肠癌转移中的分子机制。
2. **文献名称**: *Structural insights into the Ca²⁺-dependent interaction of S100A14 with integrin αvβ3*
**作者**: Wang Y et al.
**摘要**: 采用重组人源S100A14蛋白进行晶体结构解析，发现其钙离子依赖性构象变化可增强与整合素αvβ3的结合能力，为靶向肿瘤微环境的药物设计提供结构基础。
3. **文献名称**: *Recombinant S100A14 induces angiogenesis through upregulation of VEGF in endothelial cells*
**作者**: Li M et al.
**摘要**: 体外实验证实重组S100A14蛋白能剂量依赖性激活内皮细胞NF-κB通路，显著上调VEGF表达，提示其在肿瘤血管生成中的潜在调控作用。
(注：以上文献信息为基于领域知识的模拟概括，具体文献请通过PubMed或Web of Science平台检索确认)
S100A14 is a member of the S100 family of calcium-binding proteins, which are characterized by EF-hand structural motifs that enable calcium-dependent regulation. Encoded on human chromosome 1q21. S100A14 shares genomic proximity with other S100 proteins, suggesting evolutionary conservation and functional interplay. Structurally, S100A14 exists as a homodimer, binding two calcium ions per monomer, and undergoes conformational changes upon calcium activation, enabling interactions with target proteins. Its expression is tissue-specific, prominently observed in epithelial cells, and dysregulated in various cancers, including breast, colorectal, and oral squamous cell carcinomas.
Functionally, S100A14 exhibits dual roles in cancer progression, acting as either a tumor promoter or suppressor depending on cellular context. It modulates extracellular matrix remodeling, cell proliferation, migration, and apoptosis through interactions with partners like p53. matrix metalloproteinases, and integrins. Its involvement in tumor-stroma crosstalk highlights its significance in the tumor microenvironment. Additionally, S100A14 is implicated in inflammatory responses and microbial defense, reflecting its broader regulatory scope.
Recombinant S100A14 protein, typically produced in *E. coli* or mammalian expression systems, retains calcium-binding capacity and structural integrity, enabling mechanistic studies. Researchers utilize it to investigate its role in signaling pathways, protein-protein interactions, and post-translational modifications. Its potential as a therapeutic target or diagnostic biomarker drives interest in structural characterization and functional validation. Current challenges include resolving context-dependent signaling mechanisms and optimizing recombinant production for clinical applications. Ongoing studies aim to clarify its paradoxical roles in disease and leverage its therapeutic potential.
×
